diabetics
Victoza® (liraglutide) Received EU Marketing Authorization
Filed in archive Research , Treatment by Gloria Gamat on July 6, 2009
Victoza® (liraglutide) Received EU Marketing Authorization
Novo Nordisk's prime diabetes drug called Victoza® (liraglutide) has now received narketing authorization by the EU.

Victoza is the first once-daily human glucagon-like peptide-1 (GLP-1) analog developed for the treatment of type 2 diabetes and is now authorized in all 27 European Union member states for:


  • combination treatment with metformin or a sulphonylurea in patients with insufficient glycemic control despite maximal tolerated dose of monotherapy with metformin or sulphonylurea, and

  • combination treatment with metformin and a sulphonylurea or metformin and a thiazolidinedione in patients with insufficient glycemic control despite dual therapy.



Taken once daily,Victoza® is first human Glucagon-Like Peptide-1 (GLP-1) analogue. Find out more at Novo Nordisk.



Permalink: Victoza® (liraglutide) Received EU Marketing Authorization
Tags: diabetes  diabetes  Victoza  liraglutide  novo  nordisk  more  liraglutide+received 
Trackback: http://publish.creative-weblogging.com/publish/mt-tb.pl/155978
img Addthis img Ask img Blinklist img del.icio.us img Digg img Fark img Facebook img Google img Lycos img Ma.gnolia Add this page to Mister Wong Mr Wong img Netscape img Netvousz img Newsvine img Reddit img StumbleUpon img Slashdot img Tailrank img Technorati img Wink img Yahoo

Vote for Victoza® (liraglutide) Received EU Marketing Authorization:

  • Currently 10.00/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 10.00 out of 4 vote(s) cast.
Subscribe
Share It
RSSrss
See all blog subscribe options
Google google
What is RSS?
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Newsletter

TwitterFollow us on Twitter!